Gastrointestinal tolerability and quality of life in antiretroviral-naïve HIV-1-infected patients: data from the CASTLE study

Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This art...

Full description

Saved in:
Bibliographic Details
Published in:AIDS care 2010-06, Vol.22 (6), p.677-686
Main Authors: Malan, Niel, Su, Jun, Mancini, Marco, Yang, Rong, Wirtz, Victoria, Absalon, Judith, McGrath, Donnie, for the CASTLE Study Team
Format: Article
Language:English
Subjects:
Acquired immune deficiency syndrome
Adenine - adverse effects
Adenine - analogs & derivatives
Adherence
Adult
Aged
AIDS
AIDS/HIV
Anti-Retroviral Agents - adverse effects
Anti-Retroviral Agents - therapeutic use
Antiretroviral drugs
Antiretroviral therapy
Antiretroviral Therapy, Highly Active
atazanavir
Atazanavir Sulfate
Biological and medical sciences
Clinical outcomes
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Digestive system
Drug therapy
Drug Therapy, Combination
Drug toxicity and drugs side effects treatment
Emtricitabine
Female
Gastrointestinal Diseases - chemically induced
GI tolerability
Health
health-related quality of life
HIV
HIV Infections - complications
HIV Infections - drug therapy
HIV-1
Human immunodeficiency virus
Human viral diseases
Humans
Immune response system
Infectious diseases
Irritable bowel syndrome
Irritable Bowel Syndrome - chemically induced
Lopinavir
Male
Medical care
Medical sciences
Medical treatment
Medication Adherence
Middle Aged
Oligopeptides - adverse effects
Organophosphonates - adverse effects
Pharmacology. Drug treatments
Prospective Studies
Pyridines - adverse effects
Pyrimidinones - adverse effects
Quality of Life
Ritonavir - adverse effects
Surveys and Questionnaires
Tenofovir
Toxicity: digestive system
Viral diseases
Viral diseases of the lymphoid tissue and the blood. Aids
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most ritonavir-boosted protease inhibitor (PI)-based antiretroviral regimens offer comparable levels of virological efficacy. Thus, the tolerability of the regimen becomes a distinguishing factor with implications for patient quality of life (QoL), treatment adherence, and clinical outcome. This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naïve HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL). Changes in IBS-QoL from baseline over time (to week 24) were classified as: "Improvement" (≥2-point positive change from baseline), "No change" (
ISSN:0954-0121
1360-0451
DOI:10.1080/09540120903334641